Irccs Saverio Of Bellis National Institute Of Digestive Diseases

Castellana Grotte, Italy

Irccs Saverio Of Bellis National Institute Of Digestive Diseases

Castellana Grotte, Italy
SEARCH FILTERS
Time filter
Source Type

Riezzo G.,Irccs Saverio Of Bellis National Institute Of Digestive Diseases | Clemente C.,Irccs Saverio Of Bellis National Institute Of Digestive Diseases | Linsalata M.,Irccs Saverio Of Bellis National Institute Of Digestive Diseases | D'Attoma B.,Irccs Saverio Of Bellis National Institute Of Digestive Diseases | And 4 more authors.
Anticancer Research | Year: 2013

Aim: The association of motilin, ghrelin, leptin, gastrin, pepsinogen (PG) I and II with cancer chemotherapy-associated dyspepsia syndrome (CADS) was investigated in 35 patients with breast cancer receiving first cycle of 5-fluorouracil, cyclophosphamide, epirubicin (FEC60) chemotherapy. Patients and Methods: The onset of dyspeptic symptoms on days 3 and 10 after chemotherapy identified patients with and without CADS. Gastrointestinal symptoms were scored with the Gastrointestinal Symptom Scoring Rate (GSRS) questionnaire. Gastrointestinal peptides were evaluated by enzyme-linked immunosorbent assay. Results: Twenty-one patients (60%) had CADS. The area under the curve (AUC) of ghrelin was higher, whereas that of PGI, PGII and motilin were lower in patients with CADS compared to those without. In patients with CADS, the AUC of PGI and PGII negatively correlated with the GSRS indigestion cluster. Conclusion: Impairment of gastrointestinal motility suggested by low motilin concentrations and mucosal damage mirrored by an increase of ghrelin seem to be involved in the onset of CADS in patients during chemotherapy for breast cancer.

Loading Irccs Saverio Of Bellis National Institute Of Digestive Diseases collaborators
Loading Irccs Saverio Of Bellis National Institute Of Digestive Diseases collaborators